Dermata Therapeutics, Inc. (DRMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRMA Stock Price Chart Interactive Chart >
DRMA Price/Volume Stats
| Current price | $0.33 | 52-week high | $2.45 |
| Prev. close | $0.29 | 52-week low | $0.16 |
| Day low | $0.29 | Volume | 898,000 |
| Day high | $0.35 | Avg. volume | 744,250 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $0.62 | Market Cap | 4.07M |
Dermata Therapeutics, Inc. (DRMA) Company Bio
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.
Latest DRMA News From Around the Web
Below are the latest news stories about DERMATA THERAPEUTICS INC that investors may wish to consider to help them evaluate DRMA as an investment opportunity.
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea/ Dermata Therapeutics, Inc. ("Dermata" or the "Company") (Nasdaq:DRMA)(DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced topline results from its Phase 2 trial of once-weekly topical application of DMT310 for the treatment of moderate-to-severe rosacea. |
Maxim Group Reaffirms Their Buy Rating on Dermata Therapeutics (DRMA)Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Dermata Therapeutics (DRMA - Research Report) yesterday and set a price target of $4.00. The company's shares closed yesterday at $0.74.According to TipRanks, Vendetti is an analyst with an average return of -4.6% and a 32.40% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, ReShape Lifesciences, and Venus Concept.Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $4.93 and a one-year low of $0.44. Currently, Dermata Therapeutics has an average volume of 272.8K. |
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsDermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022. |
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceDermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. |
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase/ Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022. |
DRMA Price Returns
| 1-mo | 71.79% |
| 3-mo | -52.35% |
| 6-mo | -43.22% |
| 1-year | -83.25% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -19.32% |
| 2022 | -76.49% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...